Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma.

Cancer research - 15 Mar 2004

van Rhijn Bas W G, van der Kwast Theo H, Vis André N, Kirkels Wim J, Boevé Egbert R, Jöbsis Adriaan C, Zwarthoff Ellen C

Abstract excerpt

Fibroblast growth factor receptor 3 (FGFR3) and P53 mutations are frequently observed in bladder cancer. We here describe the distribution of FGFR3 mutations and P53 overexpression in 260 primary urothelial cell carcinomas. FGFR3 mutations were observed in 59% and P53 overexpression in 25%. Inter...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, p53
Share to Polymorphism, Single-Stranded Conformational
Share to Protein-Tyrosine Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Receptors, Fibroblast Growth Factor

Share to Survival Rate

Share to Urinary Bladder Neoplasms

Share to Urothelium

Source

Identifiers

PMID: 15026322
DOI: 10.1158/0008-5472.can-03-2421

Genes

FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-15026322-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma.PMID 15026322Read ↗

FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.Semantic proximity Read ↗

FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.Semantic proximity Read ↗

A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.Semantic proximity Read ↗

FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.Semantic proximity Read ↗

Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.Semantic proximity Read ↗

FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†.Semantic proximity Read ↗

FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.Semantic proximity Read ↗

Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.Semantic proximity Read ↗

Molecular intricacies of upper tract urothelial carcinoma and their relevance for therapy considerations.Semantic proximity Read ↗

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.Semantic proximity Read ↗

FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations.Semantic proximity Read ↗

FGFR3 – a Central Player in Bladder Cancer Pathogenesis?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.